Ask VialBase
Research

TB-500 (Thymosin Beta-4) for Cardiovascular Disease / ASCVD — VialBase Research

Trial Summary

Phase 1/2 trial evaluating TB-500 (a synthetic fragment of Thymosin Beta-4) for atherosclerotic cardiovascular disease. Thymosin Beta-4 is a naturally occurring 43-amino-acid peptide involved in tissue repair, anti-inflammation, and angiogenesis. Preclinical cardiac studies have shown it promotes cardiomyocyte survival, reduces fibrosis after MI, and improves cardiac function.

Design

  • Type: Randomized, placebo-controlled, dose-escalation (Phase 1) followed by expansion (Phase 2)
  • Population: Adults with established ASCVD
  • Arms: TB-500 at multiple doses vs. placebo
  • Duration: Dose-escalation phase + 6-12 month efficacy assessment
  • Key measures: Safety/tolerability (Phase 1), cardiac function, inflammatory biomarkers (hs-CRP, IL-6), plaque imaging, exercise capacity

Key Outcomes

Trial is recruiting; no results available yet.

Significance for Peptide Research

TB-500 entering formal clinical trials is a major milestone. Like BPC-157, Thymosin Beta-4 derivatives have been widely used in biohacking and veterinary medicine (horse racing) without robust human data. The cardiovascular application leverages TB-500’s tissue repair and anti-fibrotic properties. If it shows safety and biomarker improvements, this could open a new class of regenerative peptide therapeutics for heart disease, distinct from the metabolic approach of GLP-1 RAs. Relevant to regenerative peptide therapeutics and TB-500 clinical validation.

See Also